ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis

Trial Profile

ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Bixalomer (Primary)
  • Indications Hyperphosphataemia
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 17 Mar 2015 According to media release, Astellas Pharma has submitted a supplemental New Drug Application (sNDA) to the Ministry of Health, Labour and Welfare in Japan, for bixalomer [Kiklin] for treatment of hyperphosphatemia in patients with chronic kidney disease who are not on dialysis. Data from this and another phase III trial (CTP 700245026) were used in the sNDA application.
    • 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top